About Sable Bio
Sable Bio is a company based in London (United Kingdom) founded in 2023 by Josh Almond Thynne and Alex de Giorgio. Sable Bio has raised $7.85 million across 2 funding rounds from investors including Seedcamp and Episode 1 Ventures. Sable Bio offers products and services including Sable Target Intelligence. Sable Bio operates in a competitive market with competitors including Intero Biosystems, Pharmacovigilance, Mensura Health, Metsystem and EMESO, among others.
- Headquarter London, United Kingdom
- Founders Josh Almond Thynne, Alex de Giorgio
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sablebio Limited
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$7.85 M (USD)
in 2 rounds
-
Latest Funding Round
$5.96 M (USD), Series A
Sep 10, 2025
-
Investors
Seedcamp
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sable Bio
Sable Bio offers a comprehensive portfolio of products and services, including Sable Target Intelligence.
AI tool for prioritizing and mitigating drug toxicology risks.
Funding Insights of Sable Bio
Sable Bio has successfully raised a total of $7.85M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $5.96 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sable Bio
Sable Bio has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Seedcamp and Episode 1 Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed & early-stage tech-focused venture capital firm
|
Locked | Locked | Locked | |
|
Venture capital fund investing in tech startups
|
Locked | Locked | Locked |
Investor details for Sable Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sable Bio
Investment portfolio details for Sable Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sable Bio
Detailed financials for Sable Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sable Bio Comparisons
Peer comparison for Sable Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sable Bio
Sable Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Intero Biosystems, Pharmacovigilance, Mensura Health, Metsystem and EMESO, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Develops human organoids for preclinical drug testing and research applications.
|
|
| Locked | Locked | Locked |
Delivers data analytics dashboards for drug safety professionals.
|
|
| Locked | Locked | Locked |
Mensura Health is focused on epilepsy patient management solutions.
|
|
| Locked | Locked | Locked |
Offers advanced drug screens for predicting cancer metastasis and personalized treatments.
|
|
| Locked | Locked | Locked |
EMESO enhances medicines safety and efficiency with digital healthcare solutions.
|
Detailed competitors of Sable Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sable Bio
Complete news archive for Sable Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sable Bio
Sable Bio was founded in 2023 and raised its 1st funding round 1 year after it was founded.
Sable Bio is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Sable Bio is a funded company, having raised a total of $7.85M across 2 funding rounds to date.
Sable Bio was founded in 2023 and is based in London, United Kingdom. Operations focus on the pharmaceutical sector, where an AI-powered platform is utilized to evaluate clinical side effects of drugs. Potential risks during development are forecasted through data analysis, supporting safety assessments for new medications. The service aids in identifying hazards early in the drug pipeline.
Sable Bio's top competitors include Intero Biosystems, Pharmacovigilance and Mensura Health.
Sable Bio offers Sable Target Intelligence.
Sable Bio has 2 investors. Key investors include Seedcamp, and Episode 1 Ventures.